



## George W. Sledge Jr., M.D.

Professor of Medicine (Oncology) at the Stanford University Medical Center

Medicine - Oncology

 NIH Biosketch available Online

### CLINICAL OFFICES

- **Stanford Women's Cancer Center**

900 Blake Wilbur Dr

1st Fl MC 5854

Palo Alto, CA 94304

**Tel** (650) 498-6004

**Fax** (650) 498-7237

### ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Maria Carrasco - Executive Assistant

**Email** mcarrasco84@stanford.edu

**Tel** 650-724-4397

### Bio

---

### CLINICAL FOCUS

- Cancer
- Cancer > Breast Cancer
- Medical Oncology

### ACADEMIC APPOINTMENTS

- Professor - Med Center Line, Medicine - Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute

### ADMINISTRATIVE APPOINTMENTS

- Chief, Division of Oncology, Department of Medicine, (2013-2020)
- Professor, Medicine, (2013- present)

### HONORS AND AWARDS

- Ballve-Lantero Chair (Endowed Chair), Ballve-Lantero (1996)
- Editor-In-Chief, Clinical Breast Cancer (1999-present)
- Listed in "America's Top Doctors", Castle Connolly (2001-2012)
- Chair, Breast Committee, Eastern Cooperative Oncology Group (ECOG) (2002-2010)
- Komen Brinker Award for Scientific Distinction, Susan G. Komen Breast Cancer Foundation (2006)
- Jill Rose Award, Breast Cancer Foundation (2007)
- William L. McGuire Award, San Antonio Breast Cancer Symposium (2010)
- President, American Society of Clinical Oncology, American Society of Clinical Oncology (ASCO) (2010-2011)
- Health Care Hero award, Indianapolis Business Journal (2011)

- APEX Award for Publication Excellence in the category of "Regular Departments & Columns", Oncology Times (2012)
- Gianni Bonnadona Award for Breast Cancer Research, American Society of Clinical Oncology (2020)
- HOPE Funds for Cancer Research 2013 Award of Excellence for Medicine, HOPE Funds, Cancer Research (April 28, 2013)

## PROFESSIONAL EDUCATION

- Fellowship: University of Texas at San Antonio (1983) TX
- Medical Education: Tulane University School of Medicine Registrar (1977) LA
- Board Certification: Medical Oncology, American Board of Internal Medicine (1983)
- Board Certification: Internal Medicine, American Board of Internal Medicine (1980)
- Residency: St Louis University Hospital (1980) MO

## LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

## Research & Scholarship

---

### CLINICAL TRIALS

- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer, Recruiting
- Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer, Recruiting
- Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors, Recruiting
- Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer, Recruiting
- 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer, Not Recruiting
- A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors., Not Recruiting
- A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study), Not Recruiting
- A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer, Not Recruiting
- A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer, Not Recruiting
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study), Not Recruiting
- A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer, Not Recruiting
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer, Not Recruiting
- A Study of ABT-165 in Subjects With Solid Tumors, Not Recruiting
- A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC), Not Recruiting
- A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130), Not Recruiting
- A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer, Not Recruiting
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer, Not Recruiting
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone), Not Recruiting

## Publications

### PUBLICATIONS

- **The Project Baseline Health Study: a step towards a broader mission to map human health** *NPJ DIGITAL MEDICINE*  
Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., Blanco, R., Califf, R., Campbell, P., Carin, L., Christian, V., Cousins, S., Das, et al  
2020; 3 (1): 84
- **Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer.**  
Caswell-Jin, J., Callahan, A., Purington, N., Han, S. S., Itakura, H., Sledge, G. W., Shah, N., Kurian, A. W.  
AMER SOC CLINICAL ONCOLOGY.2020
- **Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.**  
Yanez, B., Gray, R., Sparano, J. A., Carlos, R., Sadigh, G., Garcia, S. F., Gareen, I. F., Whelan, T., Sledge, G. W., Cella, D., Wagner, L.  
AMER SOC CLINICAL ONCOLOGY.2020
- **MONARCH 2: Subgroup analysis of patients receiving abemaciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-advanced breast cancer.**  
Neven, P., Johnston, S. D., Toi, M., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Koh, H. A., Grischke, E., Conte, P., Lu, et al  
AMER SOC CLINICAL ONCOLOGY.2020
- **Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer**  
Grischke, E., Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Masuda, N., Kaufman, P., Koh, H., Conte, P., Barriga, et al  
KARGER.2020: 15
- **Impact of insurance and socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer**  
Obeng-Gyasi, S., O'Neil, A., Zhao, F., Kircher, S. M., Lava, T. R., Wagner, L. I., Miller, K. D., Sparano, J. A., Sledge, G. W., Carlos, R. C.  
AMER ASSOC CANCER RESEARCH.2020
- **Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials**  
Goetz, M. P., Okera, M., Wildiers, H., Campone, M., Grischke, E., Manso, L., Andre, V., Chong, A., San Antonio, B., Toi, M., Sledge, G. W.  
AMER ASSOC CANCER RESEARCH.2020
- **MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors**  
Neven, P., Johnston, S., Toi, M., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., Koh, H., Grischke, E., Conte, et al  
AMER ASSOC CANCER RESEARCH.2020
- **Clinical Significance of PIK3CA and ESR1 Mutations in CTDNA and FFPE Samples from The Monarch2 Study of Abemaciclib Plus Fulvestrant**  
Grischke, E., Tolane, S., Toi, M., Neven, P., Sohn, J., Llombart-Cussac, A., Soliman, H., Litchfield, L., Wijayawardana, S., Forrester, T. D., Jansen, V., Sledge, G. W.  
KARGER.2020: 9–10
- **Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology.** *Cancer*  
von Itzstein, M. S., Railey, E., Smith, M. L., White, C. B., Sledge, G. W., Howell, J. R., Lawton, W., Marinucci, D. M., Unni, N., Gerber, D. E.  
2020
- **Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply.** *JAMA oncology*  
Sledge, G. W., Frenzel, M.  
2020
- **Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.** *The oncologist*  
Kaufman, P. A., Toi, M., Neven, P., Sohn, J., Grischke, E. M., Andre, V., Stoffregen, C., Shekariz, S., Price, G. L., Carter, G. C., Sledge, G. W.  
2020; 25 (2): e243–e251
- **Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

- Wagner, L. I., Gray, R. J., Sparano, J. A., Whelan, T. J., Garcia, S. F., Yanez, B., Tevaarwerk, A. J., Carlos, R. C., Albain, K. S., Olson, J. A., Goetz, M. P., Pritchard, K. I., Hayes, et al  
2020: JCO1901866
- **Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.** *British journal of cancer*  
Tailor, D., Going, C. C., Resendez, A., Kumar, V., Nambiar, D. K., Li, Y., Dheeraj, A., LaGory, E. L., Ghoochani, A., Birk, A. M., Stoyanova, T., Ye, J., Giaccia, et al  
2020
  - **Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.** *Journal of the National Cancer Institute*  
Albain, K. S., Gray, R. J., Makower, D. F., Faghih, A., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., Lively, T., Badve, S. S., Saphner, T. J., Wagner, et al  
2020
  - **Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations** *JNCI CANCER SPECTRUM*  
Dowling, R. O., Kalinsky, K., Hayes, D. F., Bidard, F., Cescon, D. W., Chandarlapaty, S., Deasy, J. O., Dowsett, M., Gray, R. J., Henry, N., Meric-Bernstam, F., Perlmutter, J., Sledge, et al  
2019; 3 (4)
  - **Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions** *JNCI CANCER SPECTRUM*  
Dowling, R. O., Sparano, J. A., Goodwin, P. J., Bidard, F., Cescon, D. W., Chandarlapaty, S., Deasy, J. O., Dowsett, M., Gray, R. J., Henry, N., Meric-Bernstam, F., Perlmutter, J., Sledge, et al  
2019; 3 (4)
  - **THE ROLE OF BIG DATA AND REAL WORLD DATA**  
Sledge, G. W.  
CHURCHILL LIVINGSTONE.2019: S22
  - **Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.** *The oncologist*  
Kaufman, P. A., Toi, M., Neven, P., Sohn, J., Grischke, E., Andre, V., Stoffregen, C., Shekarriz, S., Price, G. L., Carter, G. C., Sledge, G. W.  
2019
  - **Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes** *JCO PRECISION ONCOLOGY*  
Jourquin, J., Reffey, S., Jernigan, C., Levy, M., Zinser, G., Sabelko, K., Pietenpol, J., Sledge, G.  
2019; 3
  - **Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.** *Breast cancer research : BCR*  
Ramani, V. C., Lemaire, C. A., Triboulet, M., Casey, K. M., Heirich, K., Renier, C., Vilches-Moure, J. G., Gupta, R., Razmara, A. M., Zhang, H., Sledge, G. W., Sollier, E., Jeffrey, et al  
2019; 21 (1): 98
  - **Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant**  
Tolaney, S. M., Toi, M., Neven, P., Sohn, J., Grischke, E., Llombart-Cussac, A., Soliman, H., Litchfield, L. M., Wijayawardana, S., Forrester, T., Jansen, V. M., Sledge, G. W.  
AMER ASSOC CANCER RESEARCH.2019
  - **Radiomics features to identify distinct subtypes of triple-negative breast cancers.**  
Itakura, H., Ikeda, D. M., Okamoto, S., Chen, S., Rister, B., Gude, D., Mattonen, S. A., Alkim, E., Todderud, J., Schueler, E., Rubin, D., Sledge, G. W., Kurian, et al  
AMER SOC CLINICAL ONCOLOGY.2019
  - **Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.**  
Sparano, J. A., Gray, R., Makower, D. F., Lively, T. G., Saphner, T., Keane, M. M., Gomez, H., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D., Brufsky, A., Goetz, et al

AMER SOC CLINICAL ONCOLOGY.2019

- **Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Sledge, G. W.  
2019; 116 (11): 4769–71
- **Patients and Physicians in the Era of Modern Cancer Care** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Sledge, G.  
2019; 321 (9): 829–30
- **Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer.** *Proceedings of the National Academy of Sciences of the United States of America*  
Sledge, G. W.  
2019
- **Patients and Physicians in the Era of Modern Cancer Care.** *JAMA*  
Sledge, G. W.  
2019
- **Gold Nanobipyramids as Second Near Infrared Optical Coherence Tomography Contrast Agents for in Vivo Multiplexing Studies.** *Nano letters*  
Si, P., Shevidi, S., Yuan, E., Yuan, K., Lautman, Z., Jeffrey, S. S., Sledge, G. W., de la Zerda, A.  
2019
- **The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.** *JAMA oncology*  
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., Koh, H., Grischke, E. M., Conte, et al  
2019
- **Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.** *JAMA oncology*  
Sparano, J. A., Gray, R. J., Makower, D. F., Albain, K. S., Saphner, T. J., Badve, S. S., Wagner, L. I., Kaklamani, V. G., Keane, M. M., Gomez, H. L., Reddy, P. S., Goggins, T. F., Mayer, et al  
2019
- **Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes.** *JCO precision oncology*  
Jourquin, J., Reffey, S. B., Jernigan, C., Levy, M., Zinser, G., Sabelko, K., Pietenpol, J., Sledge, G.  
2019; 3
- **Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.** *JNCI cancer spectrum*  
Dowling, R. J., Sparano, J. A., Goodwin, P. J., Bidard, F. C., Cescon, D. W., Chandralapaty, S., Deasy, J. O., Dowsett, M., Gray, R. J., Henry, N. L., Meric-Bernstam, F., Perlmutter, J., Sledge, et al  
2019; 3 (4): pkz049
- **Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.** *JNCI cancer spectrum*  
Dowling, R. J., Kalinsky, K., Hayes, D. F., Bidard, F. C., Cescon, D. W., Chandralapaty, S., Deasy, J. O., Dowsett, M., Gray, R. J., Henry, N. L., Meric-Bernstam, F., Perlmutter, J., Sledge, et al  
2019; 3 (4): pkz050
- **Real-Time Detection of Circulating Tumor Cells in Living Animals Using Functionalized Large Gold Nanorods.** *Nano letters*  
Dutta, R., Liba, O., SoRelle, E. D., Winetraub, Y., Ramani, V. C., Jeffrey, S. S., Sledge, G. W., de la Zerda, A.  
2019; 19 (4): 2334–42
- **Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.** *Clinical breast cancer*  
Upshaw, J. N., Ruthazer, R., Miller, K. D., Parsons, S. K., Erban, J. K., O'Neill, A. M., Demissei, B., Sledge, G., Wagner, L., Ky, B., Kent, D. M.  
2019

- **Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.** *JAMIA open*  
Ling, A. Y., Kurian, A. W., Caswell-Jin, J. L., Sledge, G. W., Shah, N. H., Tamang, S. R.  
2019; 2 (4): 528–37
- **Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy** *NPJ BREAST CANCER*  
Di Leo, A., O'Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., Hardebeck, M. C., Smith, I. C., Llombart-Cussac, A., Goetz, M. P., Johnston, S.  
2018; 4
- **Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial** *JAMA ONCOLOGY*  
Sparano, J., O'Neill, A., Alpaugh, K., Wolff, A. C., Northfelt, D. W., Dang, C. T., Sledge, G. W., Miller, K. D.  
2018; 4 (12): 1700–1706
- **Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies** *JCO PRECISION ONCOLOGY*  
Costa, H. A., Reyes, R., Mills, M., Zehnder, J. L., Sledge, G., Curtis, C., Ford, J. M., Suarez, C. J.  
2018; 2
- **Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)** *JOURNAL OF CLINICAL ONCOLOGY*  
Miller, K. D., O'Neill, A., Gradishar, W., Hobday, T. J., Goldstein, L. J., Mayer, I. A., Bloom, S., Brufsky, A. M., Tevaarwerk, A. J., Sparano, J. A., Le-Lindqwister, N., Hendricks, C. B., Northfelt, et al  
2018; 36 (25): 2621–+
- **Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*  
Strasser-Weippl, K., Higgins, M. J., Chapman, J. W., Ingle, J. N., Sledge, G. W., Budd, G. T., Ellis, M. J., Pritchard, K. I., Clemons, M. J., Badovinac-Crnjevic, T., Han, L., Gelmon, K. A., Rabaglio, et al  
2018; 110 (9): 1003–8
- **Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Miller, K. D., O'Neill, A., Gradishar, W., Hobday, T. J., Goldstein, L. J., Mayer, I. A., Bloom, S., Brufsky, A. M., Tevaarwerk, A. J., Sparano, J. A., Le-Lindqwister, N. A., Hendricks, C. B., Northfelt, et al  
2018: JCO2018792028
- **The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3**  
O'Shaughnessy, J., Goetz, M. P., Sledge, G. W., Martin, M., Lin, Y., Forrester, T., Smith, I. C., Di Leo, A., Johnston, S.  
AMER ASSOC CANCER RESEARCH.2018
- **TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.**  
Sparano, J. A., Gray, R., Wood, W. C., Makower, D. F., Lively, T. G., Saphner, T., Keane, M. M., Gomez, H., Reddy, P. S., Goggins, T. F., Mayer, I. A., Toppmeyer, D., Brufsky, et al  
AMER SOC CLINICAL ONCOLOGY.2018
- **Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer** *CLINICAL CANCER RESEARCH*  
Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., Seto, T., Thompson, C. A., Rigdon, J., Telli, M. L., Badve, S. S., Curtis, C. N., West, et al  
2018; 24 (12): 2851–58
- **Local Control of Distant Disease: Yes, but Where to Next?** *Journal of oncology practice*  
Sledge, G. W.  
2018; 14 (6): 357–58
- **Local Control of Distant Disease: Yes, but Where to Next?** *JOURNAL OF ONCOLOGY PRACTICE*  
Sledge, G. W.  
2018; 14 (6): 357–+

- **Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CTG) MA.27 (E1Z03) BREAST CANCER RESEARCH AND TREATMENT**  
Wagner, L. I., Zhao, F., Goss, P. E., Chapman, J. W., Shepherd, L. E., Whelan, T. J., Mattar, B. I., Bufill, J. A., Schultz, W. C., LaFrancis, I. E., Nagargoje, G. G., Vemuri, R., Nikcevic, et al  
2018; 169 (3): 537–48
- **Urgent hypertension as a biomarker for bevacizumab in the curative setting.**  
Kassem, N., Shen, F., Jiang, G., Gardner, L., Philips, S., O'Neill, A. M., Miller, K. D., Suter, T., Cameron, D. A., Sledge, G. W., Schneider, B.  
AMER SOC CLINICAL ONCOLOGY.2018
- **The association of early toxicity and outcomes for patients treated with abemaciclib**  
Rugo, H. S., Sledge, G. W., Johnston, S. D., Goetz, M. P., Martin, M., Toi, M., Forrester, T. D., Frenzel, M., Cox, J., Barriga, S., Tolaney, S. M.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies**  
Tolaney, S. M., Di Leo, A., Cussac, A., Dickler, M. N., Campone, M., Iwata, H., Toi, M., Kaufman, P. A., Andre, V. M., Barriga, S., Goetz, M. P., Sledge, G. W.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Symptom burden and employment status in breast cancer (BC) survivors.**  
Luis, I., O'Neill, A. M., Sepucha, K., Miller, K. D., Dang, C. T., Northfelt, D. W., Winer, E. P., Sledge, G. W., Schneider, B. P., Partridge, A.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2-advanced breast cancer (ABC) who progressed on endocrine therapy**  
Kaufman, P. A., Toi, M., Neven, P., Sohn, J., Price, G. L., Lin, Y., Boye, M., Li, L., Gable, J., Carter, G., Sledge, G. W.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer**  
Neven, P., Rugo, H. S., Tolaney, S. M., Iwata, H., Toi, M., Goetz, M. P., Kaufman, P. A., Barriga, S., Lin, Y., Sledge, G. W.  
AMER SOC CLINICAL ONCOLOGY.2018
- **Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers MOLECULAR CARCINOGENESIS**  
Tanaka, H., Phipps, E. A., Wei, T., Wu, X., Goswami, C., Liu, Y., Sledge, G. W., Mina, L., Herbert, B.  
2018; 57 (4): 567–75
- **Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer**  
Sparano, J. A., O'Neill, A., Alpaugh, K., Wolff, A. C., Northfelt, D. W., Dang, C., Sledge, G. W., Miller, K. D.  
AMER ASSOC CANCER RESEARCH.2018
- **Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies**  
Di Leo, A., Dickler, M., Sledge, G. W., Toi, M., Forrester, T., Nanda, S., Koustenis, A., Bourayou, N., Johnston, S.  
AMER ASSOC CANCER RESEARCH.2018
- **The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies**  
Goetz, M. P., O'Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Forrester, T., Mockbee, C., Smith, I. C., Di Leo, A., Johnston, S.  
AMER ASSOC CANCER RESEARCH.2018
- **Molecular characterization and mortality from breast cancer in men**  
Massarweh, S. A., Sledge, G. W., Miller, D. P., McCullough, D., Petkov, V. I., Shak, S.  
AMER ASSOC CANCER RESEARCH.2018
- **Molecular Characterization and Mortality From Breast Cancer in Men. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology***  
Massarweh, S. A., Sledge, G. W., Miller, D. P., McCullough, D., Petkov, V. I., Shak, S.  
2018; JCO2017768861
- **Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. *NPJ breast cancer***  
Di Leo, A., O'Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., Hardebeck, M. C., Smith, I. C., Llombart-Cussac, A., Goetz, M. P., Johnston, S.  
2018; 4: 41

- **Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review** *JNCI Cancer Spectrum*  
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., Kurian, A. W.  
2018; 2 (4)
- **Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.** *JNCI cancer spectrum*  
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., Kurian, A. W.  
2018; 2 (4): pky062
- **Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., Seto, T., Thompson, C. A., Rigdon, J., Telli, M. L., Badve, S. S., Curtis, C., West, et al  
2018
- **PRECISION/PERSONALIZED MEDICINE: HOPES AND HYPES**  
Sledge, G. W.  
CHURCHILL LIVINGSTONE.2017: S26
- **Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?** *BREAST CANCER RESEARCH AND TREATMENT*  
Partridge, A. H., Sepucha, K., O'Neill, A., Miller, K. D., Baker, E., Dang, C. T., Northfelt, D. W., Sledge, G. W., Schneider, B. P.  
2017; 165 (3): 545-53
- **A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)** *BREAST CANCER RESEARCH AND TREATMENT*  
Goldstein, L. J., Zhao, F., Wang, M., Swaby, R. F., Sparano, J. A., Meropol, N. J., Bhalla, K. N., Pellegrino, C. M., Alpaugh, R., Falkson, C. I., Klein, P., Sledge, G. W.  
2017; 165 (2): 375-82
- **Survival Benefit Needed to Undergo Chemotherapy: Patient and Physician Preferences** *CANCER*  
Vaz-Luis, I., O'Neill, A., Sepucha, K., Miller, K. D., Baker, E., Dang, C. T., Northfelt, D. W., Winer, E. P., Sledge, G. W., Schneider, B., Partridge, A. H.  
2017; 123 (15): 2821-28
- **MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.** *Journal of clinical oncology*  
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., Koh, H., Grischke, E., Frenzel, et al  
2017: JCO2017737585-?
- **MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer who progressed on endocrine therapy**  
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X. B., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., Koh, H. A., Grischke, E., Frenzel, et al  
AMER SOC CLINICAL ONCOLOGY.2017
- **Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.** *Cancer*  
Lipton, A., Chapman, J. W., Leitzel, K., Garg, A., Pritchard, K. I., Ingle, J. N., Budd, G. T., Ellis, M. J., Sledge, G. W., Rabaglio, M., Han, L., Elliott, C. R., Shepherd, et al  
2017
- **Put Some PEPI in Your Step: Ki67's Long Road to Respectability.** *Journal of clinical oncology*  
Sledge, G. W.  
2017: JCO2016712182-?
- **Research needs in breast cancer** *ANNALS OF ONCOLOGY*  
Cardoso, F., Harbeck, N., Barrios, C. H., Bergh, J., Cortes, J., El Saghir, N., Francis, P. A., Hudis, C. A., Ohno, S., Partridge, A. H., Sledge, G. W., Smith, I. E., Gelmon, et al  
2017; 28 (2): 208-217
- **Reply to L.B. Marks et al.** *Journal of clinical oncology*  
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., Hudis, C. A., Hwang, E. S., Kirshner, J. J., Morrow, M., Salerno, K. E., Sledge, G. W., Solin, et al  
2017: JCO2016713966-?



- **Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Schneider, B. P., Shen, F., Gardner, L., Radovich, M., Li, L., Miller, K. D., Jiang, G., Lai, D., O'Neill, A., Sparano, J. A., Davidson, N. E., Cameron, D., Gradus-Pizlo, et al  
2017; 23 (1): 43-51
- **Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103.** *JCO precision oncology*  
Schneider, B. P., Shen, F., Jiang, G., O'Neill, A., Radovich, M., Li, L., Gardner, L., Lai, D., Foroud, T., Sparano, J. A., Sledge, G. W., Miller, K. D.  
2017; 2017
- **Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-5103** *JCO PRECISION ONCOLOGY*  
Schneider, B. P., Shen, F., Jiang, G., O'Neill, A., Radovich, M., Li, L., Gardner, L., Lai, D., Foroud, T., Sparano, J. A., Sledge, G. W., Miller, K. D.  
2017; 1
- **Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update** *ANNALS OF SURGICAL ONCOLOGY*  
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., Hudis, C. A., Hwang, E. S., Kirshner, J. J., Morrow, M., Salerno, K. E., Sledge, G. W., Solin, et al  
2017; 24 (1): 38-51
- **Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update** *JOURNAL OF CLINICAL ONCOLOGY*  
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., Hudis, C. A., Hwang, E. S., Kirshner, J. J., Morrow, M., Salerno, K. E., Sledge, G. W., Solin, et al  
2016; 34 (36)
- **Synergistic drug combinations from electronic health records and gene expression.** *Journal of the American Medical Informatics Association*  
Low, Y. S., Daugherty, A. C., Schroeder, E. A., Chen, W., Seto, T., Weber, S., Lim, M., Hastie, T., Mathur, M., Desai, M., Farrington, C., Radin, A. A., Sirota, et al  
2016
- **Research needs in breast cancer.** *Annals of oncology*  
Cardoso, F., Harbeck, N., Barrios, C. H., Bergh, J., Cortés, J., El Saghir, N., Francis, P. A., Hudis, C. A., Ohno, S., Partridge, A. H., Sledge, G. W., Smith, I. E., Gelmon, et al  
2016
- **Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.** *Practical radiation oncology*  
Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., Hudis, C. A., Hwang, E. S., Kirshner, J. J., Morrow, M., Salerno, K. E., Sledge, G. W., Solin, et al  
2016; 6 (6): e219-e234
- **Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African-Americans.** *Oncotarget*  
Schneider, B. P., Lai, D., Shen, F., Jiang, G., Radovich, M., Li, L., Gardner, L., Miller, K. D., O'Neill, A., Sparano, J. A., Xue, G., Foroud, T., Sledge, et al  
2016
- **Aberrant nocturnal cortisol and disease progression in women with breast cancer** *BREAST CANCER RESEARCH AND TREATMENT*  
Zeitzer, J. M., Nouriani, B., Rissling, M. B., Sledge, G. W., Kaplan, K. A., Aasly, L., Palesh, O., Jo, B., Neri, E., Dhabhar, F. S., Spiegel, D.  
2016; 158 (1): 43-50
- **Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems.** *Journal of oncology practice / American Society of Clinical Oncology*  
Afghahi, A., Mathur, M., Thompson, C. A., Mitani, A., Rigdon, J., Desai, M., Yu, P. P., de Bruin, M. A., Seto, T., Olson, C., Kenkare, P., Gomez, S. L., Das, et al  
2016; 12 (6): e697-709
- **Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.**  
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D., Chabon, J. J., Scherer, F., Stehr, H., Liu, C., Bratman, S., Say, C., Zhou, L., Carter, J. N., West, et al  
AMER SOC CLINICAL ONCOLOGY.2016
- **A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.**

- Stearns, V., O'Neill, A. M., Schneider, B. P., Flockhart, D. A., Skaar, T. C., Liu, M. C., Lohrisch, C. A., Goetz, M. P., Sologuren, C., Sparano, J. A., Villa, D., Silverman, P., Cheema, et al  
AMER SOC CLINICAL ONCOLOGY.2016
- **Genome wide association study for anthracycline-induced congestive heart failure.**  
Gardner, L., Shen, F., Radovich, M., Li, L., Miller, K., Pan, G., Lai, D., O'Neill, A. M., Sparano, J. A., Davidson, N. E., Cameron, D. A., Gradus-Pizlo, I., Mastouri, et al  
AMER SOC CLINICAL ONCOLOGY.2016
  - **Association of Charcot-Marie-Tooth gene, SBF2, with taxane-induced peripheral neuropathy in African Americans.**  
Schneider, B. P., Lai, D., Shen, F., Jiang, G., Radovich, M., Li, L., Gardner, L., Miller, K. D., O'Neill, A. M., Sparano, J. A., Xue, G., Foroud, T., Sledge, et al  
AMER SOC CLINICAL ONCOLOGY.2016
  - **Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.**  
Gordon, M. S., Nemunaitis, J. J., Ramanathan, R. K., Sledge, G. W., Wang, L., Fan, X., Motwani, M., Wong, S., Morgan-Lappe, S., Iyer, S., Naumovski, L., Strickler, J. H.  
AMER SOC CLINICAL ONCOLOGY.2016
  - **Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).**  
Afghahi, A., Rigdon, J., Purington, N., Desal, M., Pierson, E., Mathur, M., Thompson, C. A., Curtis, C., West, R. B., Horst, K. C., Gomez, S., Ford, J. M., Sledge, et al  
AMER SOC CLINICAL ONCOLOGY.2016
  - **Integrated digital error suppression for improved detection of circulating tumor DNA** *NATURE BIOTECHNOLOGY*  
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., Zhou, L., Carter, J. N., West, et al  
2016; 34 (5): 547-555
  - **Collective Wisdom: Lobular Carcinoma of the Breast.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*  
Sledge, G. W., Chagpar, A., Perou, C.  
2016: 18–21
  - **Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Detour on the Road to a Cure** *JOURNAL OF CLINICAL ONCOLOGY*  
Sledge, G. W.  
2016; 34 (10): 1021–+
  - **Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology** *ONCOTARGET*  
Che, J., Yu, V., Dhar, M., Renier, C., Matsumoto, M., Heirich, K., Garon, E. B., Goldman, J., Rao, J., Sledge, G. W., Pegram, M. D., Sheth, S., Jeffrey, et al  
2016; 7 (11): 12748-12760
  - **Avoidant coping and self-efficacy mediate relationships between perceived social constraints and symptoms among long-term breast cancer survivors.** *Psycho-oncology*  
Adams, R. N., Mosher, C. E., Cohee, A. A., Stump, T. E., Monahan, P. O., Sledge, G. W., Cella, D., Champion, V. L.  
2016
  - **Quality of life difficulties in partners of young breast cancer survivors.**  
Champion, V., Cohee, A. A., Monahan, P., Stump, T. E., Miller, K., Wagner, L., Cella, D., Sledge, G.  
AMER SOC CLINICAL ONCOLOGY.2016
  - **Small-molecule binding sites to explore protein-protein interactions in the cancer proteome** *MOLECULAR BIOSYSTEMS*  
Xu, D., Jalal, S. I., Sledge, G. W., Meroueh, S. O.  
2016; 12 (10): 3067-3087
  - **Collective Wisdom: Lobular Carcinoma of the Breast.** *American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting*  
Sledge, G. W., Chagpar, A., Perou, C.  
2016; 35: 18-21

- **Curing Metastatic Breast Cancer.** *Journal of oncology practice / American Society of Clinical Oncology*  
Sledge, G. W.  
2016; 12 (1): 6-10
- **Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)** *BRITISH JOURNAL OF CANCER*  
Schneider, B. P., O'Neill, A., Shen, F., Sledge, G. W., Thor, A. D., Kahanic, S. P., Zander, P. J., Davidson, N. E.  
2015; 113 (12): 1651-1657
- **Prospective Validation of a 21-Gene Expression Assay in Breast Cancer** *NEW ENGLAND JOURNAL OF MEDICINE*  
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., Zujewski, J. A., Lively, T., Badve, et al  
2015; 373 (21): 2005-2014
- **Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199** *CLINICAL CANCER RESEARCH*  
Schneider, B. P., Li, L., Radovich, M., Shen, F., Miller, K. D., Flockhart, D. A., Jiang, G., Vance, G., Gardner, L., Vatta, M., Bai, S., Lai, D., Koller, et al  
2015; 21 (22): 5082-5091
- **IS A TWO-SPEED (RICH VS POOR) ONCOLOGY INEVITABLE?**  
Sledge, G. W.  
CHURCHILL LIVINGSTONE.2015: S34
- **A Call for Viewpoints.** *JAMA oncology*  
Sledge, G. W., Disis, M. L.  
2015; 1 (4): 432-?
- **Targeted Therapy for Cancer in the Genomic Era.** *Cancer journal*  
Afghahi, A., Sledge, G. W.  
2015; 21 (4): 294-298
- **"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.** *Clinical cancer research*  
Sledge, G. W., Pegram, M. D.  
2015; 21 (12): 2663-2665
- **Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-blind Clinical Trial of Chemotherapy for Breast Cancer** *JAMA ONCOLOGY*  
Partridge, A. H., Sepucha, K., O'Neill, A., Miller, K. D., Motley, C., Swaby, R. F., Schneider, B. P., Dang, C. T., Northfelt, D. W., Sledge, G. W.  
2015; 1 (3): 369-374
- **Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.**  
Rubinstein, M., Gray, R., Sparano, J. A., Zujewski, J., Whelan, T., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E., Perez, E. A., Keane, M. M., Vallejos, C., Goggins, et al  
AMER SOC CLINICAL ONCOLOGY.2015
- **Lymphopenia after adjuvant radiotherapy (RT) to predict poor survival in triple-negative breast cancer (TNBC).**  
Afghahi, A., Mathur, M., Seto, T., Desai, M., Kenkare, P., Horst, K. C., Das, A. K., Thompson, C. A., Luft, H. S., Yu, P., Gomez, S., Low, Y., Shah, et al  
AMER SOC CLINICAL ONCOLOGY.2015
- **Everything old is neu again: cellular senescence in HER2-positive breast cancer.** *Journal of the National Cancer Institute*  
Sledge, G. W., Pegram, M. D.  
2015; 107 (5)
- **Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer**  
Sparano, J. A., Zhao, F., Martino, S., Ligibel, J., Saphner, T., Wolff, A. C., Sledge, G. W., Perez, E. A., Wood, W. C., Davidson, N. E.  
AMER ASSOC CANCER RESEARCH.2015
- **A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2)**  
Llombart, A., Toi, M., Klise, S. R., Frenzel, M., Chan, E. M., Sledge, G. W.

AMER ASSOC CANCER RESEARCH.2015

- **Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.** *Journal of clinical oncology*  
Perez, E. A., Thompson, E. A., Ballman, K. V., Anderson, S. K., Asmann, Y. W., Kalari, K. R., Eckel-Passow, J. E., Dueck, A. C., Tenner, K. S., Jen, J., Fan, J., Geiger, X. J., McCullough, et al  
2015; 33 (7): 701-708
- **Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial** *JOURNAL OF CLINICAL ONCOLOGY*  
Perez, E. A., Thompson, E. A., Ballman, K. V., Anderson, S. K., Asmann, Y. W., Kalari, K. R., Eckel-Passow, J. E., Dueck, A. C., Tenner, K. S., Jen, J., Fan, J., Geiger, X. J., McCullough, et al  
2015; 33 (7)
- **Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients** *JOURNAL OF NEURO-ONCOLOGY*  
Duchnowska, R., Jassem, J., Goswami, C. P., Dundar, M., Goekmen-Polar, Y., Li, L., Woditschka, S., Biernat, W., Sosinska-Mielcarek, K., Czartoryska-Arlukowicz, B., Radecka, B., Tomasevic, Z., Stepniak, et al  
2015; 122 (1): 205-216
- **The future of breast cancer systemic therapy: the next 10 years.** *Journal of molecular medicine (Berlin, Germany)*  
Telli, M. L., Sledge, G. W.  
2015; 93 (2): 119-125
- **Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.** *Journal of clinical oncology*  
Stearns, V., Chapman, J. W., Ma, C. X., Ellis, M. J., Ingle, J. N., Pritchard, K. I., Budd, G. T., Rabaglio, M., Sledge, G. W., Le Maitre, A., Kundapur, J., Liedke, P. E., Shepherd, et al  
2015; 33 (3): 265-271
- **Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial** *JOURNAL OF CLINICAL ONCOLOGY*  
Stearns, V., Chapman, J. W., Ma, C. X., Ellis, M. J., Ingle, J. N., Pritchard, K. I., Budd, G. T., Rabaglio, M., Sledge, G. W., Le Maitre, A., Kundapur, J., Liedke, P. E., Shepherd, et al  
2015; 33 (3): 265-U163
- **Anti-vascular endothelial growth factor therapy in breast cancer: game over?** *Journal of clinical oncology*  
Sledge, G. W.  
2015; 33 (2): 133-135
- **Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).** *British journal of cancer*  
Schneider, B. P., O'Neill, A., Shen, F., Sledge, G. W., Thor, A. D., Kahanic, S. P., Zander, P. J., Davidson, N. E.  
2015; 113 (12): 1651-57
- **Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831** *JOURNAL OF CLINICAL ONCOLOGY*  
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., Winer, E. P., Colon-Otero, G., Davidson, et al  
2014; 32 (33): 3744-?
- **Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.** *Journal of clinical oncology*  
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., Winer, E. P., Colon-Otero, G., Davidson, et al  
2014; 32 (33): 3744-3752
- **Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.** *Nature reviews. Clinical oncology*  
Neal, J. W., Sledge, G. W.  
2014; 11 (11): 627-628
- **Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity**

- Sparano, J. A., Gray, R. J., Zujewski, J., Whelan, T., Albain, K. S., Hayes, D., Geyer, C. E., Dees, E., Perez, E. A., Keane, M. M., Sologuren, C., Goggins, T. F., Mayer, et al  
AMER SOC CLINICAL ONCOLOGY.2014
- **Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100** *BRITISH JOURNAL OF CANCER*  
Schneider, B. P., Li, L., Shen, F., Miller, K. D., Radovich, M., O'Neill, A., Gray, R. J., Lane, D., Flockhart, D. A., Jiang, G., Wang, Z., Lai, D., Koller, et al  
2014; 111 (6): 1241-1248
  - **Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.** *British journal of cancer*  
Schneider, B. P., Li, L., Shen, F., Miller, K. D., Radovich, M., O'Neill, A., Gray, R. J., Lane, D., Flockhart, D. A., Jiang, G., Wang, Z., Lai, D., Koller, et al  
2014; 111 (6): 1241-1248
  - **Improving the quality of cancer care in America through health information technology.** *Journal of the American Medical Informatics Association*  
Feeley, T. W., Sledge, G. W., Levit, L., Ganz, P. A.  
2014; 21 (5): 772-775
  - **Heterogeneity and Cancer** *ONCOLOGY-NEW YORK*  
Allison, K. H., Sledge, G. W.  
2014; 28 (9): 772-778
  - **Past, Present, and Future Challenges in Breast Cancer Treatment** *JOURNAL OF CLINICAL ONCOLOGY*  
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., Wolff, A. C.  
2014; 32 (19): 1979-1986
  - **Past, present, and future challenges in breast cancer treatment.** *Journal of clinical oncology*  
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., Wolff, A. C.  
2014; 32 (19): 1979-1986
  - **DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.** *Journal of the National Cancer Institute*  
Woditschka, S., Evans, L., Duchnowska, R., Reed, L. T., Palmieri, D., Qian, Y., Badve, S., Sledge, G., Gril, B., Aladjem, M. I., Fu, H., Flores, N. M., Gökmen-Polar, et al  
2014; 106 (7)
  - **Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103**  
Miller, K., O'Neill, A. M., Dang, C. T., Northfelt, D. W., Gradishar, W., Goldstein, L. J., Mayer, I. A., Brufsky, A., Bloom, S., Sparano, J. A., Tevaarwerk, A., Fox, K. R., Hendricks, et al  
AMER SOC CLINICAL ONCOLOGY.2014
  - **Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.**  
Perez, E. A., Thompson, E., Anderson, S., Asmann, Y. W., Kalari, K. R., Eckel-Passow, J., Dueck, A. C., Tenner, K. S., Jen, J., Fan, J., Geiger, X., McCullough, A. E., Chen, et al  
AMER SOC CLINICAL ONCOLOGY.2014
  - **A phase III randomized trial of niraparib versus physician's choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC4307-BCG and BIG5-13**  
Tryfonidis, K., Bogaerts, J., Martell, R. E., Sledge, G. W., Balmana, J., Audeh, M., Deleersnijder, A., Favorito, F., Agarwal, S., Rizzetto, G., Messina, C. M., Slaets, L., Goulioti, et al  
AMER SOC CLINICAL ONCOLOGY.2014
  - **Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103** *BREAST CANCER RESEARCH AND TREATMENT*  
Ruddy, K. J., O'Neill, A., Miller, K. D., Schneider, B. P., Baker, E., Sparano, J. A., Dang, C., Northfelt, D. W., Sledge, G. W., Partridge, A. H.  
2014; 144 (3): 591-597
  - **Delivering high-quality cancer care: The critical role of quality measurement** *HEALTHCARE-THE JOURNAL OF DELIVERY SCIENCE AND INNOVATION*  
Spinks, T. E., Ganz, P. A., Sledge, G. W., Levit, L., Hayman, J. A., Eberlein, T. J., Feeley, T. W.  
2014; 2 (1): 53-62
  - **Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing** *BREAST CANCER RESEARCH AND TREATMENT*

Radovich, M., Clare, S. E., Atale, R., Pardo, I., Hancock, B. A., Solzak, J. P., Kassem, N., Mathieson, T., Storniolo, A. M., Rufenbarger, C., Lillemoe, H. A., Blosser, R. J., Choi, et al  
2014; 143 (1): 57-68

- **Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer** *JOURNAL OF CANCER*  
Goekmen-Polar, Y., Goswami, C. P., Toroni, R. A., Sanders, K. L., Mehta, R., Sirimalle, U., Tanasa, B., Shen, C., Li, L., Ivan, M., Badve, S., Sledge, G. W.  
2014; 5 (8): 633-645
- **TCGA's Breast Cancer Project May Yield Important Therapeutic Benefits, but It's Too Early to Be Sure** *ONCOLOGY-NEW YORK*  
Radovich, M., Sledge, G. W.  
2013; 27 (12): 1280-+
- **Lessons learned from the development of the CancerLinQ prototype: Clinical decision support.**  
Schilsky, R. L., Swain, S. M., Hauser, R., Mann, J., Sledge, G. W., Yu, P., Lichter, A. S., Hudis, C.  
AMER SOC CLINICAL ONCOLOGY.2013
- **ADVANCES IN ADVANCED TRIPLE NEGATIVE BREAST CANCER**  
Sledge, G. W.  
CHURCHILL LIVINGSTONE.2013: S19
- **Biomarker prediction of chemotherapy-related amenorrhea.**  
Ruddy, K., O'Neill, A. M., Miller, K., Schneider, B. P., Baker, E., Sparano, J. A., Dang, C. T., Northfelt, D. W., Sledge, G. W.  
AMER SOC CLINICAL ONCOLOGY.2013
- **Does biomarker information impact patients' preferences for therapy?**  
Partridge, A. H., Sepucha, K., O'Neill, A., Miller, K., Baker, E., Dang, C. T., Northfelt, D. W., Sledge, G. W., Schneider, B. P.  
AMER SOC CLINICAL ONCOLOGY.2013
- **ASCO's approach to a learning health care system in oncology.** *Journal of oncology practice / American Society of Clinical Oncology*  
Sledge, G. W., Hudis, C. A., Swain, S. M., Yu, P. M., Mann, J. T., Hauser, R. S., Lichter, A. S.  
2013; 9 (3): 145-148